| [1] |
de la Fuente V, Stucker F, Saudan P. Epidemiology of community-acquired acute kidney injury[J]. Rev Med Suisse, 2014, 10 (419): 470-473.
|
| [2] |
Nassiri-Toosi Z, Dashti-Khavidaki S, Khalili H, et al. A review of the potential protective effects of pentoxifylline against drug-induced nephrotoxicity[J]. Eur J Clin Pharmacol, 2012, 69 (5): 1057-1073.
|
| [3] |
Jafari A, Dashti-Khavidaki S, Khalili H, et al. Potential nephroprotective effects of Lcarnitine against drug induced nephropathy: a review of literature[J]. Exp Opin Drug Saf, 2013, 12 (4): 523-543.
|
| [4] |
Hosseinjani H, Moghaddas A, Khalili H. Nacetylcy-steine for the prevention of non-contrast media agent-induced kidney injury: from preclinical to clinical evidence[J].Eur J Clin Pharmacol, 2013, 69 (7): 1375-1390.
|
| [5] |
Schachter M.Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update[J].Fundam Clin Pharmacol, 2005, 19 (1): 117-125.
|
| [6] |
Epstein M, Campese VM.Pleiotropic effects of 3-hydroxy-3-methylgl utaryl coenzyme: a reductase inhibitors on renal function[J].Am J Kidney Dis, 2005, 45 (1): 2214-2216.
|
| [7] |
Sharyo S, Yokota-Ikeda N, Mori M, et al.Pravastatin improves renal ischemia-reperfusion injury by inhibiting the mevalonate pathway[J].Kidney Int, 2008, 74 (5): 577-584.
|
| [8] |
Nakamura T, Sato E, Fujiwara N, et al.Atorvastatin reduces proteinuria in non-diabetic chronic kidney disease patients partly via lowering serum levels of advanced glycation end products (AGEs)[J].Oxid Med Cell Longev, 2010, 3 (5): 304-307.
|
| [9] |
Attalah N, Yassine L, Musial J, et al.The potential role of statins in contrast nephropathy[J].Clin Nephrol, 2004, 62 (4): 273-278.
|
| [10] |
Khanal S, Attallah N, Smith DE, et al.Statin therapy reduces contrast-induced nephropathy: an analysis of contemporary percutaneous interventions[J]. Am J Med, 2005, 118 (8): 843-849.
|
| [11] |
Patti G, Nusca A, Chello M, et al.Usefulness of statin pretreatment to prevent contrast-induced nephropathy to improve long-term outcome in patients undergoing percutaneous coronary intervention[J].Am J Cardiol, 2008, 101 (3): 279-285.
|
| [12] |
Zhao JL, Yang YJ, Zhang YH, et al.Effect of statins on contrast induced nephropathy in patients with acute myocardial infarction treated with primary angioplasty[J].Int J cardiol, 2008, 126 (3): 435-436.
|
| [13] |
Yoshida S, Kamihata H, Nakamura S, et al.Prevention of contrast-induced nephropathy by chronic pravastatin treatment in patients with cardiovascular disease and renal insufficiency[J].J Cardiol, 2009, 54 (2): 192-198.
|
| [14] |
Munoz MA, Maxwell PR, Green K, et al.Pravastatin versus simvastatin for prevention of contrast-induced nephropathy[J].J Cardiovasc Pharmacol Ther, 2011, 16 (3-4): 376-379.
|
| [15] |
Bouzas-Mosquera A, Vázquez-Rodríguez JM, Calvino-Santos R, et al.Statin therapy and contrast-induced nephropathy after primary angioplasty[J].Int J Cardiol, 2009, 134 (3):430-431.
|
| [16] |
Kandula P, Shah R, Singh N, et al.Statins for prevention of contrast-induced nephropathy in patients undergoing non-emergent percutaneous coronary intervention[J].Nephrology, 2010, (Carlton) 15 (2): 165-170.
|
| [17] |
Jo SH, Koo BK, Park JS, et al.Prevention of radiocontrast medium-induced nephropathy using short-term high-dose simvastatin in patients with renal insufficiency undergoing coronary angioplasty (PROMISS) trial- a randomized controlled study[J].Am Heart J, 2008, 155 (3): 499.
|
| [18] |
Xinwei J, Xianghua F, Jing Z, et al.Comparison of usefulness of simvastatin 20 mg versus 80 mg in preventing contrast-induced nephropathy in patients with acute coronary syndrome undergoing percutaneous coronary intervention[J].Am J Cardiol, 2009, 104 (4): 519-524.
|
| [19] |
Toso A, Maioli M, Leoncini M, et al.Usefulness of atorvastatin 80 mg in prevention of contrast-induced nephropathy in patients with chronic renal disease[J].Am J Cardiol, 2010,105 (3):288-292.
|
| [20] |
Ozhan H, Erden I, Ordu S, et al.Efficacy of short-term high-dose atorvastatin for prevention of contrast-induced nephropathy in patients undergoing coronary angiography[J].Angiology, 2010, 61(7):711-714.
|
| [21] |
Acikel S, Muderrisoglu H, Yildirir A, et al.Prevention of contrast-induced impairment of renal function by short-term or long-term statin therapy in patients undergoing elective coronary angiography[J]. Blood Coagul Fibrinolysis, 2010, 21 (8):750-757.
|
| [22] |
Patti G, Ricottini E, Nusca A, et al.Short-term, high-dose storvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndrome undergoing percutaneous coronary intervention (from the ARMYDA-CIN [Atortvastatin for reduction of myocardial damage during angioplasty-contrast-induced nephropathy] trial)[J].Am J Cardiol, 2011, 108 (1): 1-7.
|
| [23] |
Li W, Fu X, Wang Y, et al.Beneficial effects of high-dose atorvastatin pre-treatment on renal function in patients with acute ST-segment elevation myocardial infarction undergoing emergency percutaneous coronary intervention[J].Cardiology, 2012, 22 (3): 195-202.
|
| [24] |
Quintavalle C, Fiore D, De Micco F, et al.Impact of high loading dose of atorvastatin on contrast-induced acute kidney injury[J].Circulation, 2012, 126 (25): 3008-3016.
|
| [25] |
Lopez-Novoa JM, Quiros Y, Vicente L, et al.New insight into the mechanism of aminoglycoside nephrotoxicity: an integrative point of view[J].Kidney Int, 2011, 79 (1): 33-45.
|
| [26] |
Antoine DJ, Srivastava A, Pirmohamed M, et al.Statins inhibit aminoglycoside accumulation and cytotoxicity to renal proximal tubule cells[J].Biochem Pharmacol, 2010, 79 (4): 647-654.
|
| [27] |
Ozbek E, Cekmen M, Ilbey YO, et al.Atorvastatin prevents gentamicin-induced renal damage in rats through the inhibition of p38-MAPK and NF-B pathways[J]. Ren Fail, 2009, 31 (5): 382-392.
|
| [28] |
Jabari M, Rostami Z, Jenabi A, et al. Simvastatin ameliorates gentamicin-induced renal injury in rats[J]. Saudi J Kidney Dis Transpl, 2011, 22 (6): 1181-1186.
|
| [29] |
Iranian Registry of Clinical Trials. Atorvastatin efficacy on prevention of aminoglycosids-induced nephrotoxicity. Teharn, Iran, IRCT201301283449N11, 2014.
|
| [30] |
Elyasi S, Khalili H, Dashti-Khavidaki S, et al. Vancomycin-induced nephrotoxicity: mechanisms, incidence, risk factors and special populations: a literature review[J]. Eur J Clincal Pharmacol, 2012, 68 (9):1243-1255.
|
| [31] |
Ladino M, Alex M, Schulman IH. Acute and reversible vancomycin nephrotoxicity: a case series[J]. J Nephrol Res Transplant, 2008, 3: 4-10.
|
| [32] |
Nishino Y, Takemura S, Minamiyama Y, et al. Targeting superoxide dismutase to renal proximal tubule cells attenuates vancomycin-induced nephrotoxicity in rats.Free Rad Res, 2003, 37 (4): 372-379.
|
| [33] |
Hazlewood KA, Brouse SD, Pitcher WD, et al. Vancomycin-associated nephrotoxicity: grave concern or death by character assassination?[J]. Am J Med, 2011, 123 (2): 182-187.
|
| [34] |
King DW, Smith MA. Proliferative responses observed following vancomycin treatment in renalproximal tubule epithelial cells[J]. Toxicol In Vitro, 2004, 18 (6): 797-803.
|
| [35] |
Panonnummal R, Varkey J, Dinoop DR. Protective effects of atorvastatin against vancomycin induced nephrotoxicity in albino rats[J]. Pharmacie Globale, 2011, 2 (8):1-6.
|
| [36] |
Miller RP, Tadagavadi RK, Ramesh G, et al. Mechanisms of cisplatin nephrotoxicity[J]. Toxins (Basel), 2011, 2 (11): 2490-2518.
|
| [37] |
Chirino YI, Pedraza-Chaverri J. Role of oxidative and nitrosative stress in cisplatin-induced nephrotoxicity. Exp Toxicol Pathol, 2009, 61 (3): 223-242.
|
| [38] |
Ramesh G, Reeves WB. P38 MAP kinase inhibition ameliorates cisplatin nephrotoxicity in mice[J]. Am J Physiol Renal Physiol, 2005, 289 (1): F166-174.
|
| [39] |
Chan KK, Oza AM, Siu LL. The statins as anticancer agents[J]. Clin Cancer Res, 2003, 9 (1): 10-19.
|
| [40] |
Iseri S, Ercan F, gedik N, et al. Simvastatin attenuates cisplatin- induced kidney and liver damage in rats[J]. Toxicology, 2007, 230 (2-3): 256-264.
|
| [41] |
Khoshnoud MJ, Abdeh Moghbel BN, Geramizadeh B, et al. Effect of simvastatin on cisplatin-induced nephrotoxicity in male rats[J]. Iranian Journal of Pharmaceutical Sciences, 2011, 7 (3): 165-173.
|
| [42] |
Fujieda M, Morita T, Naruse K, et al. Effects of pravastatin on cisplatin-induced nephrotoxicity in rats[J]. Hum Exp Toxicol, 2010, 30 (7): 603-615.
|
| [43] |
An Y, Xin H, Yan W, et al. Amelioration of cisplatin-induced nephrotoxicity by pravastatin in mice[J]. Exp Toxicol Pathol, 2011, 63 (3): 215-219.
|
| [44] |
Roudier E, Mistafa O, Stenius U. Statins induce mammalian target of rapamycin (mTOR)-mediated inhibition of Akt signaling and sensitize p53-deficient cells to cytostaic drugs[J]. Mol Cancer Ther, 2006, 5 (11): 2706-2715.
|
| [45] |
Finlay GA, Malhowski AJ, Liu Y, et al. Selective inhibition of growth of tuberous sclerosis complex 2 null cells by atorvastatin is associated with impaired Rheb and Rho GTPase function and reduced mTOR/S6kinase activity[J]. Cancer Res, 2007, 67 (20): 9878-9886.
|
| [46] |
Sharyo S, Yokota-Ikeda N, Mori M, et al. Pravastatin improves renal ischemia-reperfusion injury by inhibiting the mevalonate pathay[J]. Kidney Int, 2008, 74 (5): 577-584.
|
| [47] |
Cheng CF, Juan SH, Chen JJ, et al. Pravastatin attenuates carboplatin- induced cardiotoxicity via inhibition of oxidative stress associated apoptosis[J]. Apoptosis, 2008, 13 (7): 883-894.
|
| [48] |
Kalam K, Marwick TH. Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis[J]. Eur J Cancer, 2013, 49 (13): 2900-2909.
|
| [49] |
Naesens M, Kuypers DRS, Sarwal M. calcineurin inhibitor nephrotoxicity[J]. Clin J Am Soc Nephrol, 2009, 4 (12): 481-508.
|
| [50] |
Li C, Yang CW, Park JH, et al. Pravastatin treatment attenuates interstitial inflammation and fibrosis in a rat model of chronic cyclosporine-induced nephropathy[J]. Am J Physiol Renal Physiol, 2004, 286 (1): F46-F57.
|
| [51] |
Nam HK, Lee SJ, Kim MH, et al. Rosuvastatin attenuates inflammation, apoptosis, and fibrosis in a rat model of cyclosporine- induced nephropathy[J]. Am J Nephrol, 2013, 37 (1): 7-15.
|
| [52] |
Riella LV, Gabardi S, Chandraker A. Dyslipidemia and its therapeutic challenge in renal transplantation[J]. Am J Transplant, 2012, 12 (8): 1975-1982.
|
| [53] |
Maharjan N, Bedi U, Arora R, et al. Impact of statins on cardiovas- cular outcomes in renal transplant recipients: a systematic review[J]. Am J Ther, 2011, 18 (3): e48-e54.
|
| [54] |
Mehra MR, Raval NY. Metaanalysis of statins and survival in de novo cardiac transplantation[J]. Transplant Proc, 2004, 36 (5): 1539-1541.
|
| [55] |
Stein W, Schrepfer S, Itoh S, et al. Prevention of transplant coronary artery disease by prenylation inhibitors[J]. J Heart Lung Transplant, 2011, 30 (7): 761-769.
|
| [56] |
Dipiro JI, Talbert RL, Yee GC, et al. Pharmacotherapy: a pathophysiologic approach[M].8th.New York, United States: McGraw-Hill, 2011.
|